Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 3/20 | 0.35 |
| ▸ | TOP2A | P11388 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.32 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8775559 | 0.89 | TOP2A (0.35) | TOP2ANOTUM | |
| SCHEMBL17775397 | 0.80 | TOP2A (0.42) | TOP2ANOTUMFFAR4 | |
| SCHEMBL16329562 | 0.79 | TOP2A (0.55) | TOP2AFFAR4 | |
| SCHEMBL8775774 | 0.79 | ALDH1A1 (0.32) | P2RX7FFAR4 | |
| SCHEMBL23515078 | 0.78 | TOP2A (0.42) | PDE4ATOP2A | |
| SCHEMBL22015414 | 0.77 | TOP2A (0.44) | TOP2ANOTUMFFAR4 | |
| SCHEMBL21894264 | 0.76 | TOP2A (0.42) | TOP2ANOTUMFFAR4 | |
| SCHEMBL12737551 | 0.73 | TOP2A (0.40) | TOP2ANOTUMFFAR4 | |
| SCHEMBL27283901 | 0.72 | NOTUM (0.32) | PDE4AP2RX7NOTUMALPLFFAR4 | |
| SCHEMBL22774826 | 0.71 | PDE4A (0.42) | PDE4AALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238694-B2 | Rifamycin imino derivatives effective against drug-resistant microbes | CUMBRE PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20050209210-A1 | Rifamycin imino derivatives effective against drug-resistant microbes | CUMBRE INC. (US) | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209210-A1 | Rifamycin imino derivatives effective against drug-resistant microbes | RIF1, TOP1, TOP2A | PDE4A 1229/4885TOP2A 3/4885P2RX7 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.